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Some studies suggested that proprotein convertase subtilisin kexin type 9 (PCSK9) is
linked to liver steatosis severity and non-alcoholic steatohepatitis (NASH). We aimed
to assess whether circulating PCSK9 levels are associated with either liver fat
content (LFC) or histological markers of NASH in high-risk patients.
Methods
We present results from three cross-sectional studies from two French Hospitals:
Dijon and Numevox (departments of Endocrinology) and Angers (department of
Hepatology). Only patients without lipid-lowering therapy were included. All 132
patients had type 2 diabetes in Dijon, compared to 55/224 in Numevox (25%) and
39/122 in Angers (32%). LFC was assessed on MRI (Dijon and Numevox), and NASH
lesion on liver biopsy (Angers). Additionally, we included mRNA results from 138
overweight patients of a Belgian Hospital (Antwerp).
Results
While circulating levels of PCSK9 were positively correlated with total cholesterol,
LDL-C, triglycerides and non-HDL-C in all 3 cohorts, no significant association was
found between PCSK9 and transaminases. Furthermore, no association was found
between plasma PCSK9 levels and LFC in both Numevox (βadjusted = 0.71 ± 1.33,
p = 0.60) and Dijon (βadjusted = −1.03 ± 0.90, p = 0.25). There was no correlation
between circulating PCSK9 and histological liver lesions: steatosis severity
(βadjusted = −3.95 ± 2.75, p = 0.15), NASH activity score (βadjusted = −0.31 ± 0.17,
p = 0.082), lobular (β = −0.067 ± 0.055, p = 0.22) or portal inflammation
(β = −0.088 ± 0.079, p = 0.27), ballooning (β = −0.025 ± 0.065, p = 0.70) and fibrosis
(β = −0.17 ± 0.11, p = 0.12). Finally, hepatic PCSK9 mRNA levels were not correlated
with NASH histological severity.
Conclusions
Circulating PCSK9 concentrations are not associated with the severity of liver
steatosis or histological markers of NASH. These data are reassuring regarding the
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